FDA showdown over Moderna flu shot sparks fears of anti-vaccine bias
TL;DR Summary
The FDA declined to review Moderna’s experimental mRNA flu vaccine, citing an allegedly inadequate trial design for adults 65 and older that used a standard-dose control instead of a high-dose option, prompting critics to allege an anti-vaccine agenda and a chilling effect on vaccine development; Moderna and its supporters argue the design was approved and that higher-dose controls should have informed the analysis.
- FDA refuses to consider Moderna flu shot in move experts claim is part of ‘anti-vaccine agenda’ The Guardian
- FDA refuses to review Moderna’s application for mRNA flu vaccine, company says CNN
- FDA’s Prasad Weathers Personal Controversy, Internal Strife Amid Moderna Imbroglio BioSpace
- FDA refuses to review Moderna's influenza vaccine application Reuters
- Moderna’s president weighs in on FDA’s decision not to review its flu vaccine statnews.com
Reading Insights
Total Reads
0
Unique Readers
8
Time Saved
6 min
vs 7 min read
Condensed
95%
1,210 → 63 words
Want the full story? Read the original article
Read on The Guardian